13 January 2025

Etcembly unveils first look at EMLy™ Copilot - a powerful AI platform for immunotherapy engineering

Oxford, UK - Techbio pioneer Etcembly is soft-launching their new immune engineering platform, EMLy™ Copilot, during the 43rd annual JPM Healthcare Conference.

Etcembly’s AI engine, EMLy™, aims to be the world’s most powerful platform for immune engineering. It seamlessly integrates cutting-edge bioinformatics, large language models (LLMs) and structural modelling tools with billions of antibody and T cell receptor (TCR) sequences from unique proprietary and public sources.

EMLy Copilot is a user-friendly natural language interface allowing intuitive exploration of the data and tools within EMLy to discover and engineer novel immunotherapies. By combining a vast immune repertoire library with the creativity of generative AI, EMLy Copilot enables researchers to find real proteins that bind to their target and then iterate to make something new.

Etcembly’s senior leadership - CEO Michelle Teng, CTO Jacob Hurst, CSO Nick Pumphrey and CFO Beckie Bown - will be at the JPM Healthcare Conference in San Francisco from 13-16 January to showcase EMLy Copilot to the research and investment communities.

Michelle Teng says:

With EMLy Copilot, we want to make creating the next life-changing immunotherapy as simple as hitting ‘search’. By making our platform accessible in this way we hope to create a playground for protein engineering, where everything you need to explore, experiment and create is at your fingertips to bring forward the next generation of therapeutics.

For further information or to request a demo, visit etcembly.io/emly-co-pilot